North America Ocular Drug Delivery Market Growth and Forecast by 2028

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028

North America Ocular Drug Delivery Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (Implantable Ocular Drug Delivery Systems, Particulate Drug Delivery Systems, Nano-Particle Drug Delivery System, and Others), Formulation Type (Liposomes and Nanoparticles, Solution, Emulsion, Suspension, and Ointment), Disease Type (Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Macular Degeneration, Cataract, Diabetic Macular Edema, and Others), and End User (Hospitals, Ophthalmic Clinics, and Ambulatory Surgical Centers)

  • Report Date : Nov 2021
  • Report Code : TIPRE00025761
  • Category : Life Sciences
  • Status : Published
  • Available Report Formats : pdf-format excel-format
  • No. of Pages : 147

The ocular drug delivery market in North America is expected to grow to US$ 10,622.77 million by 2028 from US$ 6,286.54 million in 2021. The market is estimated to grow at a CAGR of 7.8% from 2021 to 2028.


Cataract, glaucoma, age-related macular degeneration, diabetic retinopathy, and unaddressed refractive error are among the leading causes of blindness or low vision. Most of the population have or had some eye disorder in their lifetime. As per the World Health Organization (WHO) report "Blindness and vision impairment" published in February 2021, around 2.2 billion people worldwide have a near or distance vision impairment. It has also estimated that the leading cause of vision loss or low vision is cataract (94 million) and uncorrected refractive errors (88.4 million). Further, the other common causes of vision loss are glaucoma (7.7 million), corneal opacities (4.2 million), diabetic retinopathy (3.9 million), and trachoma (2 million). According to the National Eye Institute (NEI), in the US, the number of people with cataracts is expected to double from 24.4 million in 2010 to about 50 million in 2050. Similarly, as per the Factsheet Glaucoma: Facts & Figures 2019, over 3 million people in the US were living with glaucoma.  Moreover, as per the Canadian Survey on Disabilities 2017, 1.5 million Canadians had a sight loss, and around 5.59 million had an eye disease which could further lead to sight loss.

Amidst the COVID-19 crisis, the healthcare institutions have witnessed decrees in inpatient visits to clinics to prevent the spread of the COVID-19 in the first and second quarters of 2020. As per the recent study by CDC, the number of medical emergency department (ED) visits has declined 42% during the early COVID-19. As a result, the number of elective eye procedures performed per week in hospitals and clinics has decreased over time. According to an article in Ophthalmology Times, elective procedures have decreased in countries such as the United States. The number of patient visits to examination facilities has reduced by 15%. During the COVID-19 pandemic, ophthalmology lost a considerable share of patient volume; the volume of ophthalmic practice is predicted to have decreased by 81%, owing to a decline in patients seeking care for glaucoma and cataracts surgery.

With the new features and technologies, companies can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the ocular drug delivery market. The North America ocular drug delivery market is expected to grow at a good CAGR during the forecast period.
North America ocular drug delivery market
  • This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

North America Ocular Drug Delivery Market Segmentation

North America Ocular Drug Delivery Market – By Technology

  • Implantable Ocular Drug Delivery Systems
  • Particulate Drug Delivery Systems
  • Nano-Particle Drug Delivery System
  • Others

North America Ocular Drug Delivery Market – By Formulation Type

  • Solution
  • Ointment
  • Suspension
  • Emulsion
  • Liposomes and Nanoparticles

North America Ocular Drug Delivery Market – By Disease type

  • Cataract
  • Dry Eye Syndrome
  • Macular Degeneration
  • Glaucoma
  • Diabetic Retinopathy
  • Diabetic Macular Edema
  • Others

North America Ocular Drug Delivery Market – By End User

  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgical Centers

North America Ocular Drug Delivery Market – By Country

  • US
  • Canada
  • Mexico

North America Ocular Drug Delivery Market – Companies Mentioned

  • AbbVie Inc.                                              
  • Bausch Health Companies Inc.            
  • Novartis AG                                            
  • Clearside Biomedical, Inc                      
  • Ocular Therapeutix, Inc.                       
  • Envisia Therapeutics                             
  • Alimera Sciences, Inc.                           
  • EYEGATE PHARMACEUTICALS, INC     

North America Ocular Drug Delivery Report Scope

Report Attribute Details
Market size in 2021 US$ 6,286.54 Million
Market Size by 2028 US$ 10,622.77 Million
Global CAGR (2021 - 2028) 7.8%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By Technology
  • Implantable Ocular Drug Delivery Systems
  • Particulate Drug Delivery Systems
  • Nano-Particle Drug Delivery System
By Formulation Type
  • Liposomes and Nanoparticles
  • Solution
  • Emulsion
  • Suspension
  • Ointment
By Disease Type
  • Glaucoma
  • Diabetic Retinopathy
  • Dry Eye Syndrome
  • Macular Degeneration
  • Cataract
  • Diabetic Macular Edema
By End User
  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgical Centers
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Market leaders and key company profiles
  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Novartis AG
  • Clearside Biomedical, Inc
  • Ocular Therapeutix, Inc.
  • Envisia Therapeutics
  • Alimera Sciences, Inc.
  • EYEGATE PHARMACEUTICALS, INC
  • Mrinal Kerhalkar
    Mrinal Kerhalkar
    Manager,
    Market Research & Consulting

    Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

    Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

    • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
    • PEST and SWOT Analysis
    • Market Size Value / Volume - Global, Regional, Country
    • Industry and Competitive Landscape
    • Excel Dataset

    Testimonials

    user

    I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.

    DR CHIJIOKE ONYIA, MANAGING DIRECTOR, PineCrest Healthcare Ltd.
    user

    The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services

    Yukihiko Adachi CEO, Deep Blue, LLC.

    Reason to Buy

    • Informed Decision-Making
    • Understanding Market Dynamics
    • Competitive Analysis
    • Customer Insights
    • Market Forecasts
    • Risk Mitigation
    • Strategic Planning
    • Investment Justification
    • Identifying Emerging Markets
    • Enhancing Marketing Strategies
    • Boosting Operational Efficiency
    • Tracking Industry Innovations
    • Aligning with Regulatory Trends
    Your Key Concerns Addressed - Question & Answer
    Can I view a sample of the report before purchasing?

    Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.

    Is analyst support included with the purchase?

    Absolutely — analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.

    What are the next steps once I place an order?

    Once your order is successfully placed, you will receive a confirmation email along with your invoice.

    • For published reports: You’ll receive access to the report within 4–6 working hours via a secured email sent to your email.
    • For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.

    Can the report be tailored to suit my specific needs?

    We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope.

    In what format is the report delivered?

    The report is available in either PDF format or as an Excel dataset, depending on the license you choose.

    The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
    Please review the license options at checkout or contact us to confirm which formats are included with your purchase.

    How secure is the payment process on your platform?

    Our payment process is fully secure and PCI-DSS compliant.

    We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
    You can make your purchase with confidence, knowing your personal and financial information is safe with us.

    Do you provide special pricing for buying multiple reports?

    Yes, we do offer special pricing for bulk purchases.
    If you're interested in purchasing multiple reports, we’re happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you’re considering, and we’ll share a personalized quote.

    Can I connect with your team to discuss the report before buying?

    Yes, absolutely.
    Our team is available to help you make an informed decision. Whether you have questions about the report’s scope, methodology, customization options, or which license suits you best, we’re here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.

    Will I get a billing invoice upon purchase?

    Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
    If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we’ll be happy to assist.

    Is there support available if I can’t access my report?

    Yes, certainly.
    If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we’ll ensure the issue is resolved quickly so you can access your report without interruption.

    Our Clients
    1. AbbVie Inc.                                              
    2. Bausch Health Companies Inc.            
    3. Novartis AG                                            
    4. Clearside Biomedical, Inc                      
    5. Ocular Therapeutix, Inc.                       
    6. Envisia Therapeutics                             
    7. Alimera Sciences, Inc.                           
    8. EYEGATE PHARMACEUTICALS, INC                                                            
    Sales Assistance
    US: +1-646-491-9876
    UK: +44-20-8125-4005
    Email: sales@theinsightpartners.com
    Chat with us
    DUNS Logo
    87-673-9708
    ISO Certified Logo
    ISO 9001:2015
    ISO Certified Logo